Researchers conducted this systematic review and meta-analysis to determine the weight, BMI, cardiometabolic and gastrointestinal effects of glucagon-like peptide-1 (GLP-1) receptor agonists in children with obesity.
Data were obtained from 574 children and adolescents, 302 of which received a GLP-1RA. GLP-1 receptor agonists use caused a modest decline in body weight, BMI, and BMI z-score. In children with proven insulin resistance, glycemic control was improved. This meta-analysis found that GLP-1 receptor agonists are safe and effective in clinical settings for reducing weight, BMI, HbA1c, and systolic blood pressure in children and adolescents with obesity, though with increased rates of nausea.